ABSTRACT
It is remarkable how the treatment of lipid disorders has moved in just over a decade from the domain of a few interested secondary care specialists to become a mainstream activity for all primary care professionals. Clearly, this represents an appreciation of the burden of atherosclerotic vascular disease at large, the clarification of the central, causative role of dyslipidaemia and the emergence of incontrovertible evidence of benefit from lipid-modifying trials.
